Skip to main content
Algernon Health Inc. logo

Algernon Health Inc. — Investor Relations & Filings

Ticker · AGN CSE Human health and social work activities
Open in API
Filings indexed 308 across all filing types
Latest filing 2025-07-01 Capital/Financing Update
Country CA Canada
Listing CSE AGN

About Algernon Health Inc.

https://www.algernonhealth.com/

Algernon Health Inc. is a healthcare company focused on the provision of advanced diagnostic services, primarily through the establishment of medical clinics specializing in Alzheimer's disease. A key offering is the utilization of brain-optimized Positron Emission Tomography (PET) scanning technology for screening and imaging within a planned network of North American facilities. The company maintains a clinical-stage drug development and repurposing division, which investigates existing, approved drugs for new therapeutic applications targeting unmet global medical needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing amended terms and closing details for a non-brokered private placement (financing) and details on warrant pricing, tranches, and use of proceeds. It relates to the company’s capital raising activity rather than financial results or board changes, matching the Capital/Financing Update category.
2025-07-01 English
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a press release announcing a non-brokered private placement of equity and warrants (financing activity). It provides details on share issuance, pricing, use of proceeds, closing date, and terms—typical of a Capital/Financing Update. There is no indication it is an earnings release, management commentary, regulatory filing, or report publication notice.
2025-05-27 English
52-109F2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a standalone certification (Form 52-109FV2) of interim filings by the CFO, not the interim financial report itself. It is short, refers to the filings under securities legislation, and serves a regulatory compliance role rather than presenting financial results or management discussion. There is no substantive financial data or MD&A content beyond the certification. It therefore falls under the fallback category for miscellaneous regulatory filings.
2025-04-29 English
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 certification by the CEO certifying the review and fair presentation of the issuer’s interim financial report and interim MD&A for the period ended February 28, 2025. It is a certification form required under Canadian securities rules for venture issuers, and does not itself contain the interim financial statements or MD&A narrative. It is not the interim report (IR) itself, nor an announcement of report publication, but a regulatory certification filing with no other fitting category. Therefore, it should be classified under the fallback Regulatory Filings category (RNS).
2025-04-29 English
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion and Analysis” for the six months ended February 28, 2025 and contains management’s narrative on operations, financial performance, forward-looking statements, business environment, and risks. This aligns exactly with the definition of a Management Report (MD&A), rather than a full interim/quarterly financial filing or other announcement. Therefore, the correct classification is MDA.
2025-04-29 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Interim Consolidated Financial Statements' for Algernon Pharmaceuticals Inc. for the six-month period ended February 28, 2025. It contains comprehensive financial statements, including the Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Cash Flows, and Statement of Changes in Shareholders' Equity, along with detailed explanatory notes. This meets the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H2 2025
2025-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.